Just on two weeks since the Azer-Cel FDA Fast track announcement and since then IMU has dropped 25% in value (4c down to 3c) to hit an almost 5 yr low. Basically nothing to show for 5 yrs of work from a share price point of view and this is in an environment where there have been no negative announcements. God help us if there were to be negative announcements. Would be interesting to see what the CEO's salary was back in May 2020 compared to now, given that the market caps were very similar.
Seems we are an eternity away from any juicy positive news on efficacy of treatments, which appears will be the only trigger to drive the price up. Announcements such as we have been granted a patent, or will be presenting a paper, or we are attending a conference or paid for broker reports, just don't cut it any more. The market wants to see progress on positive efficacy results and not just one complete response.
So buying opportunity below 3c or catching a falling knife?
IMU Price at posting:
3.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)